Cerevel Therapeutics Holdings, Inc. operates as a clinical-stage biopharmaceutical company engages in the development of various therapies for neuroscience diseases. Its products include CVL-231, a positive allosteric modulator (PAM) that is in an ongoing Phase 1b multiple ascending dose and pharmacokinetic/pharmacodynamic trials for the treatment of patients with schizophrenia; and CVL-865, a PAM that is in Phase 2 proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as intends to initiate a Phase 1 proof-of-principle trials in acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase 3 program for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase 1 single ascending dose trials for the treatment of substance use disorder (SUD). It is also involved in the development of various preclinical compounds for various neuroscience indications. The company was founded in 2018 and is headquartered in Boston, Massachusetts.